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Abstract: Euglobal-IIIa (1), a novel acylphloroglucinol-sesquiterpene derivative, and a known analogue, have been isolated from 
leaves of Eucalyptus robusta. The structures was elucidated by extensive spectroscopic data and by comparison with data reported 
in literature, while the absolute configuration of 1 was determined by the X-ray diffraction analysis. Compound 1 exhibited compa-
rable cytotoxicity with that of cisplatin against five human cancer cell lines HL-60, SMMC-7721, A-549, MCF-7, and SW480 with 
IC50 values of 15.7, 15.5, 17.6, 14.3, and 21.8 μM, respectively. 
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Introduction 
Euglobals are a group of caryophyllene-based monoterpe-
noid (or sesquiterpenoid) derivatives which have been found 
to be abundant in the genus Eucalyptus.1 Pharmacological 
investigations of them showed antitumor, antimicrobial, and 
granulation inhibiting activities.2 As part of our efforts to 
search for significant antitumor agents, a novel acylphloroglu-
cinol-sesquiterpene derivative, named euglobal-IIIa (1), and a 
known analogure, were isolated from leaves of E. robusta 
Smith, a tree up to 20 meters distributed in Yunnan and Si-
chuan province, China. The structure of 1 was established on 
the basis of extensive spectroscopic methods and the absolute 
configuration was determined by the single crystal X-ray dif-
fraction analysis, while the known compound was identified as 
sideroxylonal B (2) by comparison with data reported in litera-
ture.3 The cytotoxicity of two compounds against five human 
cancer cell lines was evaluated. 
 
Results and Discussion 
An acetone extract of E. Robusta was partitioned between 
H2O and EtOAc. The isolation of the EtOAc lay afforded a 
new caryophyllene-based terpenoid, named as euglobal-IIIa 
(1), along with an analogue, sideroxylonal B (2). 
Euglobal-IIIa (1), colorless crystals, was found to posssess a 
molecular formula of C28H40O6 as assigned by HREIMS at m/z 
472.2828 [M]+ (calcd. 472.2825 [M]+), implying nine degrees 
of unsaturation. The UV spectrum showed the existence of a 
phenyl group based on the maximum absorption bands at 282 
and 232 nm, while the FT-IR spectrum exhibited absorption 
bands for carbonyl groups (1629 cm−1) and hydroxy groups 
(3556 and 3441 cm−1). 
 
The 1H NMR spectrum displayed two downfield singlets at 
δH 10.15 (1H, s) and 9.98 (1H, s) ascribable for two aldehyde 
groups, an oleanfic signal at δH 5.29 (1H, dd, J = 6.4, 3.2 Hz), 
six methyl signals (including four singlets at δH 1.07, 1.24, 
1.28, and 1.69 and two doublets at δH 0.71 and 0.91) (Table 1). 
The 13C NMR spectrum displayed 28 carbon resonances which 
could be assigned as nine quaternary carbons, seven methines, 
six methylenes, and six methyls (Table 1). These information 
suggested that compound 1 possessed three rings. Of the 
carbon resonances, six quaternary signals at δC 105.7, 169.0, 
103.8, 167.8, 104.6, and 163.9, together with two aldehyde 
carbons at δC 191.8 (d) and 191.9 (d) established an 
acylphloroglucinol moiety (ring A, Figure 1).1d,1g,4 Preliminary 
analysis of 1H–1H COSY spectrum readily established an 
isopentane group which was connected to C-1 as revealed by 
the key HMBC correlation of δH 2.68 (1H, m, H-7) with δC 
105.7 (C-1), 163.6 (s, C-2), and 169.0 (s, C-6) (Figure 1). 
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Further analyses of 1H–1H COSY spectrum established another 
two partial structures a and b, which were linked to form the 
ring C according to HMBC correlations including δH 2.09 (1H, 
m, H-1') with δC 85.1 (s, C-10') and 36.2 (d, C-7), δH 2.03 (1H, 
m, H-3′a) and 2.28 (1H, m, H-3′b) with δC 134.4 (s, C-4'), and δH 1.80 (2H, m, H-9′) with δC 85.1 (s, C-10') (Figure 1). In 
addition, a methyl signal at δH 1.69 (3H, s, H-15') showing 
HMBC correlations with δC 134.4 (s, C-4') and 41.5 (t, C-3') 
suggested the methyl placed at C-4', while the correlation of δH 
1.07 (3H, s, H-14') with δC 85.1 (s, C-10') suggested another 
methyl placed at C-10' (Figure 1). The rest three carbon 
signals of δC 73.5 (s), 18.5 (q), and 29.0 (q) established a 
hydroxy substituted isopropyl placed at C-7' as revealed by 
HMBC correlation of δH 1.87 (1H, m, H-7') with δC 73.5 (s, C-
11') (Figure 1). Since compound 1 possessed three ring in the 
structure as elaborated above and in order to fit the mass unit, 
there must be an ether bond between C-2 and C-10' to 
established ring C (Figure 1), which was also supported by the 
comparison of 13C NMR data of C-1, C-2, C-7, C-1', C-10' 
with other analogues.1a,1d,4 Therefore, the planar structure of 1 
was established.  
To establish the stereoconfiguration of 1, an ROESY 
spectrum was measured. In which, the cross peak between H-7 
and H-14' suggested H-7 and Me-14' in the same side, and the 
cross peak of H-15' with H-6' suggested E form of double 
bond between C-4' and C-5'. However, the stereoconfiguration 
of C-1' and C-7' could not be determined according to the 
ROESY spectrum. Finally, an X-ray diffraction not only 
confirmed the structure of 1 but also established the absolute 
configuration of the whole molecule (Figure 1). 
Both compounds 1 and 2 were evaluated for their cytotoxi-
city against five human cancer lines using the MTT method as 
reported previously.5 Cisplatin was used as the positive control. 
The results showed that compound 1 displayed comparable 
cytotoxicity with that of cisplatin against SMMC-7721, A-549, 
MCF-7, and SW480, while compound 2 was inactive to all the 
tested strains (IC50 > 40 μM) (Table 2). 
 
Experimental Section 
General Experimental Procedures. Melting points were 
determined on an X-4 micro melting point apparatus. Optical 
rotations were measured with a Horiba SEPA-300 polarimeter. 
UV spectra were obtained using a Shimadzu UV-2401A spec-
trophotometer. IR spectra were obtained by a Tenor 27 spec-
trophotometer with KBr pellets. 1D and 2D spectra were run 
on a Bruker DRX-500 spectrometer with TMS as an internal 
standard. Chemical shifts (δ) were expressed in ppm with ref-
erence to the solvent signals. Mass spectra were recorded on a 
Waters AutoSpec Primier P776 instrument or an API QSTAR 
Pulsar i spectrometer. X-ray diffraction was performed on a 
Bruker SMART APEX-II diffractometer using graphitemono-
chromated Cu Kα radiation. Column chromatography (CC) 
was performed using silica gel (200–300 mesh and H, Qingdao 
Marine Chemical Co. Ltd., Qingdao, People’s Republic of 
China). Fractions were monitored by TLC (GF254, Qingdao 
Marine Chemical Co. Ltd., Qingdao), and spots were visual-
ized by heating silica gel plates sprayed with 10% H2SO4 in 
EtOH. All solvents were distilled prior to use. 
 
Plant Material. The leaves of E. robusta were obtained 
from Kunming Botanical Garden, Kunming, China, and identi-
fied by Prof. Xiao Chen. A specimen (No. 2009716E) has 
been deposited at Kunming Institute of Botany, Chinese Acad-
emy of Sciences. 
 
Extraction and Isolation. An air-dried sample (5 kg) was 
extracted in acetone at room temperature, and a crude extract 
was obtained after three times, which was partitioned between 
H2O and EtOAc. The EtOAc lay was separated by CC over 
silica gel (100–200 mesh, Qindao Marine Chemical Ltd., Chi-
na) eluted with petroleum ether : acetone in a gradient of 0:1 
Table 1. 1H and 13C NMR data for 1 (CDCl3,  in ppm and J in 
Hz).a 
No. δH δC No. δH δC 
1  105.7 (s) 2' 1.47 m 32.5 (t) 
2  163.9 (s) 3' 2.03 m 
2.28 m 
41.5 (t) 
3  104.6 (s) 4'  134.4 (s) 
4  167.8 (s) 5' 5.29 dd (6.4, 3.2) 123.9 (d) 
5  103.8 (s) 6' 2.25 m 25.1 (t) 
6  169.0 (s) 7' 1.87 m 44.7 (d) 
7 2.68 m 36.2 (d) 8' 1.61 m 
1.81 m 
21.2 (t) 
8 10.15 s 191.9 (d) 9' 1.80 m 33.8 (t) 
9 9.98 s 191.8 (d) 10'  85.1 (s) 
10 1.53 m 
2.19 m 
37.9 (t) 11'  73.5 (s) 
11 1.54 m 25.2 (d) 12' 1.24 s 28.5 (q)c 
12 0.71 d (6.1) 23.8 (q)b 13' 1.28 s 29.0 (q)c 
13 0.91 d (6.1) 24.3 (q)b 14' 1.07 s 21.6 (q) 
1' 2.09 m 39.8 (d) 15' 1.69 s 16.6 (q) 
aData were assigned based on the HSQC and HMBC spectra. 
b,cAssignments may be reversed. 
 
Figure 1.  Key 2D NMR correlations of 1 with the X-ray 
structure showing absolute configuration. 
Table 2. Cytotoxicity of 1 and 2 (IC50, μM). 
 HL-60 SMMC-7721 A-549 MCF-7 SW480 
1 15.7 15.5  17.6  14.3 21.8  
2 > 40 > 40 > 40 > 40 > 40 
Cisplatina 0.9  17.1  16.0  14.9  19.1  
aPositive control. 
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→ 1:1 to afford six fractions (a → e). Fraction b was purified 
by repeated CC over silica gel (200–300 mesh, Qindao Marine 
Chemical Ltd., China) eluted with petroleum ether : EtOAc in 
a gradient of 9:1 → 5:5 to afford five fractions, and euglobal-
IIIa (1) (20 mg) precipitated from the second one. Compound 
2 (50 mg) was obtained from fraction d after CC over silica gel 
eluted with CHCl3 : MeOH (8:1). 
 
Euglobal-IIIa (1): colorless crystals (MeOH); mp 182–184 
C; [α]22D + 142.9 (c 0.05, CHCl3); UV (CHCl3) λmax (log ε): 
282 (3.93), 232 (3.37), 207 (3.42), 202 (3.42), 192 (3.41); IR 
(KBr) νmax: 3556, 3441, 2951, 1629, 1442, 1313, 1177, 860 
cm−1; 1H and 13C NMR data, see Table 1; EIMS m/z 472 [M]+; 
HREIMS m/z 472.2828 [M]+ (calcd for C28H40O6, 472.2825). 
 
Crystal data for euglobal-IIIa (1): C28H40O6, M = 472.60; 
orthorhomic, space group P212121; a = 8.11740(10) Å, b = 
10.9874 (2) Å, c = 29.3316 (5) Å,  = 90.00, β = 90.00, γ = 
90.00, V = 2616.06 (7) Å3, Z = 4, d = 1.2000 g/cm3, crystal 
dimensions 0.45 × 0.25 × 0.15 mm was used for measurement 
on a Bruker SMART APEX-II diffractometer using graphite-
monochromated Cu Kα radiation. The total number of reflec-
tions measured was 9380, of which 4335, were observed, I > 
2σ(I). Final indices: R1 = 0.0599, wR2 = 0.1719. Crystallo-
graphic data for the structure of 1 have been deposited in the 
Cambridge Crystallographic Data Centre (deposition number 
CCDC 809489). Copies of the data can be obtained free of 
charge from the CCDC via www.ccdc.cam.ac.uk 
 
Cytotoxicity Assay. Five human cancer cell lines, breast 
cancer MCF-7, hepatocellular carcinoma SMMC-7721, human 
myeloid leukemia HL-60, colon cancer SW480, and lung can-
cer A-549 cells, were used in the cytotoxic assay. All the cells 
were cultured in RPMI-1640 or DMEM medium (Hyclone, 
USA), supplemented with 10% fetal bovine serum (Hyclone, 
USA) in 5% CO2 at 37 C. The cytotoxicity assay was per-
formed according to the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) method in 96-well micro-
plates.5 Briefly, 100 µL adherent cells were seeded into each 
well of 96-well cell culture plates and allowed to adhere for 12 
h before drug addition, while suspended cells were seeded just 
before drug addition with initial density of 1 × 105 cells/mL. 
Each tumor cell line was exposed to the test compound dis-
solved in DMSO at concentrations of 0.0625, 0.32, 1.6, 8, and 
40 μM in triplicates for 48 h, with cisplatin (Sigma, USA) as a 
positive control. After compound treatment, cell viability was 
detected and a cell growth curve was graphed. IC50 values 
were calculated by Reed and Muench’s method.6 
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